Product Description
Vedolizumab Biosimilar. (Sourced from: https://www.alvotech.com/pipeline)
Mechanisms of Action: a4b7 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alvotech
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for AVT-16](https://pryzm-maps.s3.us-west-2.amazonaws.com/193current_maps.png)
Countries in Clinic: Croatia, Georgia, Latvia, New Zealand, Slovakia
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Colitis, Ulcerative
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AVT16-GL-C01 | P3 |
Not yet recruiting |
Colitis, Ulcerative |
2026-06-01 |
|
AVT16-GL-C01 | P3 |
Not yet recruiting |
Colitis, Ulcerative |
2026-03-31 |
|
AVT16-GL-F01 | P1 |
Active, not recruiting |
Healthy Volunteers |
2024-10-16 |